Personalised Medicine and Clinical Trials On Target Therapy” in Oncology, Research or Business?

In the last decades personalized medicine and the so called “target therapy” became the new paradigm in oncology and an increasing number of “target drugs” have been built-up by the industry for treatment of advanced cancer disease. Likely frustration due to incurability in most instances and some advances has favored the arising of the new paradigm. In spite many target drugs so far have entered into clinical practice and take part of the guidelines recommended by many international scientific societies, median survival in the most common types of advanced cancer and fatal outcome of these patients did not substantially change[1-3]. Only small subsets in different types of advanced cancers have shown to significantly benefit from some of these new drugs.